• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by CNS Pharmaceuticals Inc.

    11/12/25 5:00:13 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CNSP alert in real time by email
    DEFA14A 1 cns_defa14a.htm FORM DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

    (Amendment No.           )

     

     

    Filed by the Registrant x

    Filed by a Party other than the Registrant ¨

     

    Check the appropriate box:

     

    o Preliminary Proxy Statement
    o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    o Definitive Proxy Statement
    x Definitive Additional Materials
    o Soliciting Material Pursuant to §240.14a-12

     

     

    CNS Pharmaceuticals, Inc.

    (Name of Registrant as Specified In Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

     

    Payment of Filing Fee (Check the appropriate box):

     

    x No fee required.

     

    o Fee paid previously with preliminary materials.

     

    o Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

     

     

     

     

       

     

     

    CNS Pharmaceuticals, Inc.

    2100 West Loop South, Suite 900

    Houston, TX 77027

    (800) 946-9185

     

    SUPPLEMENT TO PROXY STATEMENT
    FOR
    ANNUAL MEETING OF STOCKHOLDERS
    To Be Held on November 17, 2025 at 12:00pm Eastern Time

     

    On October 24, 2025, CNS Pharmaceuticals, Inc. (the “Company”) filed its definitive proxy statement for its annual meeting of stockholders to be held on November 17, 2025 (the “Proxy Statement”) with the Securities and Exchange Commission. The Company is providing this supplement (this “Supplement”) solely to correct an error in the form of proxy included with the Proxy Statement that was filed (the “Proxy Card”). The Proxy Card mailed to stockholders was corrected prior to the mailing.

     

    Proposal 4 on the Proxy Card, which provides the Company’s stockholders a vote, on a non-binding, advisory basis, for their preference as to how frequently to hold future votes to approve the compensation of the Company’s named executive officers (commonly referred to as "say-on-pay" frequency), has been corrected to provide stockholders the option to vote “1 Year,” “2 Years,” “3 Years,” or to “Abstain.” The corrected Proxy Card is presented on the following page of this Supplement. The Proxy Statement itself and the link for voting by internet each contain reference to the correct Proxy Card. All other information contained in the Proxy Statement and Proxy Card is correct and no other changes have been made to the Proxy Statement or the Proxy Card.

     

    This Supplement should be read in conjunction with the Proxy Statement, and other than the revisions described above, this Supplement does not modify or supersede any information in the Proxy Statement. From and after the date of this Supplement, any references to the “Proxy Statement” are to the Proxy Statement as supplemented hereby. If you have already voted, you do not need to vote again unless you would like to change or revoke your prior vote on any proposal. If you would like to change or revoke your prior vote on any proposal, please refer to the section titled "May I revoke my proxy?" in the Proxy Statement for specific instructions on how to do so.

     

    Important Notice Regarding the Availability of Proxy Materials

    for the Annual Stockholder Meeting to be Held on November 17, 2025:

    Electronic copies of this Supplement, the Proxy Statement, and the Company’s Annual Report on Form 10-K for the

    fiscal year ended December 31, 2024 are available at

    http://icomproxy.com/cnsp

     

     

     

     

     

     2 

     

     

     

    REVOCABLE PROXY CNS PHARMACEUTICALS APPOINTMENT OF PROXY SOLICITED BY THE BOARD OF DIRECTORS ANNUAL MEETING OF SHAREHOLDERS – NOV. 17, 2025 AT 12:00 P.M., EASTERN TIME The undersigned stockholder acknowledges receipt of the Notice of Annual Meeting of Stockholders and the Proxy Statement, each dated October 24 , 2025 , and hereby appoints John Climaco and Christopher Downs, or either of them, proxies for the undersigned, each with full power of substitution, to vote all of the undersigned’s shares of common stock of CNS Pharmaceuticals, Inc . (the “Company”) at the Annual Meeting of Stockholders of the Company to be held virtually at https : //westcoaststocktransfer . com/proxy - CNSP/, on November 17 , 2025 at 12 : 00 P . M . Eastern Standard Time, and at any adjournments or postponements thereof . PLEASE SIGN, DATE AND RETURN THE PROXY IN THE ENVELOPE ENCLOSED . THIS PROXY WILL BE VOTED IN THE MANNER DIRECTED HEREIN BY THE UNDERSIGNED STOCKHOLDER . IF NO DIRECTION IS MADE, THIS PROXY WILL BE VOTED FOR THE NOMINEES SET FORTH IN PROPOSAL 1 , AND FOR THE PROPOSALS SET FORTH IN ITEMS 2 - 7 . THIS PROXY WILL REVOKE ALL PRIOR PROXIES SIGNED BY YOU . (CONTINUED AND TO BE SIGNED ON REVERSE SIDE.) VOTING INSTRUCTIONS Read our proxy statement before you vote by proxy. MAIL: Please mark, sign, date, and return this Proxy Card promptly using the enclosed envelope. Complete the reverse portion of this Proxy Card and Fax to 760 - 452 - 4423 . FAX: INTERNET: https://www.westcoaststocktransfer.com/proxy - CNSP/ CONTROL NUMBER: . . Go to the above Internet website . Have your proxy card in hand when you access the website . Enter your "Control Number" printed above and then follow the instructions provided to appoint the Proxies and give them directions on how to vote your shares . If you appoint the Proxies by Internet, you need not return a proxy card . You will be appointing the Proxies to vote your shares for you on the same terms and with the same authority as if you marked, signed and returned a proxy card . You may appoint the Proxies by Internet until 11 : 59 P . M . EDT Nov 16 , 2025 using your control number shown above .

       

     

     

     

    ANNUAL MEETING OF SHAREHOLDERS PLEASE COMPLETE, DATE, SIGN AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE. PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE:  CONTROL NUMBER: CONTROL NUMBER: FOR ALL Proposal 1 EXCEPT WITHHOLD ALL FOR ALL Proposal 1    ELECTION OF DIRECTORS: Proposal to elect six (6) nominees to the Board of Directors.  John Climaco  Jerzy (George) Gumulka  Jeffrey R. Keyes  Faith Charles   Bettina Cockroft Amy Mahery ABSTAIN Proposal 2 AGAINST FOR Proposal 2     ed public To ratify the appointment of MaloneBailey, LLP as the Company’s independent register accounting firm for the year ending December 31, 2025. Proposal 3 FOR AGAINST ABSTAIN  Proposal 3    To vote on a non - binding, advisory resolution to approve executive compensation. Proposal 4 ABSTAIN 1 YEAR 2 YEARS 3 YEARS  Proposal 4 To vote on a non - binding, advisory proposal on the frequency of holding future votes regarding executive compensation.     ABSTAIN Proposal 5 AGAINST FOR  Proposal 5    To approve an amendment to the Company’s Amended and Restated Articles of Incorporation to increase the total number of authorized shares of common stock from 25 , 000 , 000 shares to 300 , 000 , 000 shares and the total number of authorized shares of preferred stock from 416 , 667 shares to 5 , 000 , 000 shares . Proposal 6 ABSTAIN AGAINST FOR  Proposal 6 To approve amendments to the Company’s 2020 Stock Plan including an increase in the number of shares of common stock authorized for issuance under the Company’s 2020 Stock Plan.    Proposal 7 ABSTAIN AGAINST FOR  Proposal 7    To authorize the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting or adjournment or postponement thereof to approve the above proposals.  NOTE: In their discretion, upon such other matters as may properly come before the meeting. IMPORTANT : Please sign exactly as your name or names appear on this Proxy . When shares are held jointly, each holder should sign . When signing as executor, administrator, attorney, trustee or guardian, please give full title as such . If the signer is a corporation, please sign full corporate name by duly authorized officer, giving full title as such . If signer is a partnership, please sign in partnership name by authorized person . Dated : , 2025 The board of directors recommends a vote FOR the nominees and proposals 2 and 3, FOR 1 YEAR for proposal 4, and FOR Proposals 5 through 7. If no specification is made, the shares will be voted for such nominees and proposals. (Print Name of Shareholder and/or Joint Tenant) (Signature of Shareholder) (Second Signature if held jointly)

       

     

     

    Get the next $CNSP alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CNSP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CNSP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Keyes Jeffry R.

    4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

    11/19/25 9:07:48 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Executive Officer Climaco John M

    4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

    11/19/25 5:00:07 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Charles Faith L.

    4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

    11/19/25 5:00:04 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNSP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IBN Announces Latest Episode of The BioMedWire Podcast Featuring John Climaco, CEO of CNS Pharmaceuticals Inc.

    AUSTIN, Texas, Aug. 27, 2025 (GLOBE NEWSWIRE) -- -- via IBN -- IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features John Climaco, CEO of CNS Pharmaceuticals Inc. (NASDAQ:CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary a

    8/27/25 8:00:00 AM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024

    Live webcast discussion featuring internationally renowned Glioblastoma Multiforme (GBM) Key Opinion LeadersCompany committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cureRegister for the event here HOUSTON, TX / ACCESSWIRE / December 5, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it will host a Virtual Analyst & Investor Day on Wednesday, December 11th from 11:30 AM - 1:00 PM ET.For the event, John Climaco, C

    12/5/24 9:10:00 AM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

    Poster presented at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025 HOUSTON, TX / ACCESSWIRE / November 25, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the presentation of updated results from the on-going potentially pivotal study evaluating Berubicin, the Company's novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier

    11/25/24 9:00:00 AM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNSP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Gumulka Jerzy bought $10,000 worth of shares (33,333 units at $0.30), increasing direct ownership by 345% to 43,006 units (SEC Form 4)

    4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

    2/6/24 10:28:10 AM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evans Carl Anthony bought $10,000 worth of shares (33,333 units at $0.30), increasing direct ownership by 26,666% to 33,458 units (SEC Form 4)

    4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

    2/6/24 10:27:56 AM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Downs Christopher bought $20,000 worth of shares (66,666 units at $0.30), increasing direct ownership by 181% to 103,438 units (SEC Form 4)

    4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

    2/6/24 10:27:39 AM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNSP
    SEC Filings

    View All

    CNS Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - CNS Pharmaceuticals, Inc. (0001729427) (Filer)

    11/21/25 5:19:16 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by CNS Pharmaceuticals Inc.

    SCHEDULE 13G/A - CNS Pharmaceuticals, Inc. (0001729427) (Subject)

    11/14/25 6:40:32 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by CNS Pharmaceuticals Inc.

    10-Q - CNS Pharmaceuticals, Inc. (0001729427) (Filer)

    11/14/25 5:10:42 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNSP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Brookline Capital initiated coverage on CNS Pharmaceuticals with a new price target

    Brookline Capital initiated coverage of CNS Pharmaceuticals with a rating of Buy and set a new price target of $10.00

    2/2/21 10:31:34 AM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNSP
    Leadership Updates

    Live Leadership Updates

    View All

    Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors

    Highly accomplished biopharmaceutical industry executive with successful track record in the commercialization and launch of drugs in varied therapeutic areas including oncology, neurology, and immunologyHOUSTON, TX / ACCESSWIRE / January 18, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has appointed Amy Mahery to its Board of Directors, effective upon completion of a financing. Ms. Mahery, who currently serves as the Chief Commercial Officer of Roivant Sciences, a $9 Billion market cap b

    1/18/24 8:45:00 AM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CNS Pharmaceuticals Appoints Faith L. Charles, JD as Chair of the Board of Directors

    Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations HOUSTON, Jan. 3, 2023 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has appointed Faith L. Charles as Chair of its Board of Directors. "The depth and breadth of knowledge, experience and network that Fait

    1/3/23 12:00:00 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Esports Technologies Adds Deep Expertise in Corporate Finance and Operations With Appointment of Christopher Downs to its Board of Directors

    LAS VEGAS, March 16, 2021 /PRNewswire/ -- Esports Technologies, Inc., a global provider of advanced esports wagering products, today announced the appointment of Christopher Downs to its Board of Directors, effective March 5, 2021. Downs will lend his years of corporate finance experience to Esports Technologies as it accelerates its growth in esports wagering. As a board member of Esports Technologies, Downs will chair the Audit Committee and serve on both the Compensation and Nominating and Governance Committees. Esports Technologies Adds Deep Expertise in Corporate Finance and Operations With Appointment of Christopher Downs to its Board of Directors Aaron Speach, Esp

    3/16/21 9:03:00 AM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNSP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CNS Pharmaceuticals Inc.

    SC 13G/A - CNS Pharmaceuticals, Inc. (0001729427) (Subject)

    11/14/24 3:58:53 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by CNS Pharmaceuticals Inc.

    SC 13D - CNS Pharmaceuticals, Inc. (0001729427) (Subject)

    8/2/24 4:11:48 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by CNS Pharmaceuticals Inc.

    SC 13G - CNS Pharmaceuticals, Inc. (0001729427) (Subject)

    7/2/24 12:34:25 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care